Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton May 22, 2022 11:58am
208 Views
Post# 34701155

RE:RE:RE:New paper on MTf-pep

RE:RE:RE:New paper on MTf-pep
I should have more clearly stated the difference between liver-produced LSD enzymes and the xB3 enzymes that Bioasis can manufacture.
 
Bioasis xB3 drugs are generally understood to be produced as fusion proteins by genetically programmed mammalian cell lines, as WuXi does, or maybe other methods such as Protalix's ProCellEx plant cell manufacturing system. Either way, the drug is expressed by the cells, harvested, tweaked, processed and put in containers ready to be injected into patients.
 
The method in this new paper causes the liver to produce the drugs so that no enzyme injections are required. There may be periodic gene therapy injections to keep liver production at required levels, but basically, this method causes the patient's own body to produce the required enzyme, and that enzyme, because the peptide forms a part of it, can cross the BBB, thereby eliminating enzyme replacement therapy.
 
jd
<< Previous
Bullboard Posts
Next >>